Shape Therapeutics Unveils AAVidâ„¢ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy

▴ Shape Therapeutics Unveils AAVidâ„¢ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

Shape Therapeutics, Inc. a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

The AAVidTM capsid discovery platform uses non-random mutational fitness to create massive capsid libraries of billions of unique AAV variants for direct-to-NHP in vivo biological selection. By combining cutting-edge DNA synthesis, advanced synthetic biology, next-generation sequence barcoding, and machine learning algorithms, ShapeTX generates industry-leading library size and diversity to enable the development of best-in-class human therapeutics.

 

“Wildtype first-generation AAVs are enabling the recent advances in gene therapy, but they have been plagued by toxicities in the clinic due in part to a lack of tissue specificity, resulting in the need for high doses. Our AAVidTM platform solves the issue by creating novel capsid variants with specific tissue-tropism,” said Francois Vigneault Ph.D., President, and CEO at ShapeTX. “We’ve stayed quiet for the past three years while developing a superior AAV platform technology and are excited to announce that we have best-in-class AAV variants in hand. Today, we are announcing our novel liver-tropic AAV5 variants – stay tuned for more to come.”

 

David J. Huss, Ph.D., Vice President and Head of Research added, “The vast structural space for exploration at the AAV capsid/target cell interface necessitates enormous library size and diversity, which until now, has only been probed with capsid library sizes in the tens of thousands to millions. At ShapeTX, we set out to create a superior AAV capsid discovery platform with library sizes in the billions of unique variants, thereby maximizing the opportunity for novel virus/target cell interactions.” Dr. Huss presented the details of the platform at the 2nd RNA Editing Summit on Dec. 2, 2020.

 

About Shape Therapeutics, Inc

Shape Therapeutics is a biotechnology company developing next-generation RNA-targeted therapies to treat the world’s most challenging diseases. The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfixTM, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVidTM, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!

Tags : #ShapeTherapeutics #GeneTherapyCompany #AAVidCapsid #AAVid #AAV5 #DavidJHuss #RNAfix #RNAskip

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Bitter Truth Behind Sweet Treats: Hidden Cancer Risks in Your Favorite CakesOctober 03, 2024
Ageing Faster Than You Think? Discover How a Simple Cheek Swab Could Save Your LifeOctober 03, 2024
The University of Tasmania invites international student applications for their Tasmanian International ScholarshipOctober 03, 2024
A New Hope for Type 1 Diabetes: Tackling Blood Sugar Drops with Somatostatin BlockersOctober 03, 2024
Prostate Cancer Strikes Young: The Alarming Rise of Aggressive Cases in Men Under 50October 03, 2024
Fleetguard Filters Private Limited (FFPL) Wins Prestigious ‘Iconic Brands of India 2024’ at the This recognition adds to Fleetguard's growing list of accolades, further establishing its position as a leader in the automotive industry. The company remains dedicated to advancing innovation and providing solutions that consistently meet the changing needs of its customers.October 03, 2024
Mr. Piush Srivastava, Head of Marketing and Corporate Communications of Fleetguard Filters Pvt. Ltd, Awarded 'Marketing Maverick' by Dun & Bradstreet October 01, 2024
Chikungunya Strikes Back: The Forgotten Virus Making a Deadly ComebackOctober 01, 2024
The Hidden Cancer Risk in Your Morning Routine: How Poor Oral Hygiene May Be Endangering Your HealthOctober 01, 2024
Toxic Wrappings: Is Your Food Packaging Linked to Breast Cancer?September 30, 2024
My body, Is it my own?September 30, 2024
A Cure for Type 1 Diabetes? The Game-Changing Power of Stem Cell TherapySeptember 30, 2024
The Future of Health: Why Ayurveda's Inclusion in Ayushman Bharat is a MilestoneSeptember 30, 2024
Nutriwiz Launches Affordable Milk Mixes to Combat Micronutrient Deficiencies at ISF 2024September 28, 2024
World Heart Day- Tetsuya Yamada - Managing Director, OMRON Healthcare India.September 28, 2024
Amritapuri Celebrates Amma's 71st BirthdaySeptember 28, 2024
Is Poor Sleep During Pregnancy Setting Your Baby Up for Developmental Challenges?September 28, 2024
Can India Save Modern Medicine? The War Against Antimicrobial Resistance Begins HereSeptember 28, 2024
Mpox Clade I: The Deadly Virus India's Fighting to ContainSeptember 28, 2024
From Desk to Date: Quick Hair Transformations for busy ProfessionalsSeptember 27, 2024